A study analysing patient reported experiences of immunotherapy and targeted therapies for metastatic melanoma using health-related social media
Latest Information Update: 08 Oct 2020
At a glance
- Drugs Binimetinib (Primary) ; Dabrafenib/trametinib (Primary) ; Encorafenib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms EXCITE
- 08 Oct 2020 New trial record
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress